Centene stock plunges after surprise loss and soaring medical costs

Centene Corp. shares plunged nearly 10% after the health insurer reported a surprise Q2 adjusted loss of 16 cents per share, significantly missing analyst expectations for an 11-cent profit, despite robust revenue growth. The unexpected loss was primarily driven by a surge in its health benefits ratio to 93%, indicating soaring medical costs across its Medicaid and ACA businesses. Compounding investor concerns, Centene drastically slashed its 2025 adjusted EPS forecast to $1.75 from previous guidance of over $7.25, reflecting escalating industry-wide pressures from elevated care utilization and regulatory uncertainty.

Analysis

Centene Corporation's (CNC) second-quarter results reveal a significant deterioration in profitability, driven by uncontrollable medical costs that overshadowed a robust 22% year-over-year revenue increase to $48.7 billion. The company reported a surprise adjusted loss of 16 cents per share, starkly contrasting with analyst expectations for an 11-cent profit. The primary driver of this miss was a surge in the health benefits ratio to 93%, well above the 87.6% reported a year ago and the 91.3% consensus estimate, indicating that premium revenues are being rapidly consumed by care expenses in its Medicaid and ACA segments. The most alarming signal for investors is the drastic reduction of the 2025 adjusted EPS forecast to $1.75, a collapse from prior guidance of over $7.25 and significantly below the Wall Street estimate of $4.65. This guidance revision suggests management anticipates these margin pressures are not transient but structural. The issues are systemic across the health insurance sector, with peers like Molina and Elevance also flagging cost pressures, compounded by regulatory headwinds such as potential changes to Medicaid enrollment and the 2026 expiration of ACA subsidies, creating a highly uncertain forward-looking environment.

Key Decisions for Investors

• The severe cut in 2025 EPS guidance to $1.75 from over $7.25 requires a fundamental reset of valuation models, as it signals a long-term impairment of Centene's earnings power.
• Investors should closely monitor the health benefits ratio in coming quarters, as any failure to bring this key metric down from the current 93% level will indicate continued, severe margin compression.
• Given the challenges are sector-wide, with similar warnings from peers and looming regulatory risks, it may be prudent to reduce exposure to the managed care space or implement hedges until cost utilization trends stabilize.